MediPharm Labs Corp. will release its third-quarter financial results for the three and nine months ended September 30th, 2025, before markets open on November 13th, 2025. An executive management team conference call and webcast will also be held on the same day at 10:00 a.m. (Eastern time). Participants can dial in at (888) 330-2454 for North America or +1 (240) 789-2714 for international callers, with the conference ID being 4921762. For those unable to join live, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after the call. Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients, and advanced derivative products. In 2021, MediPharm received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale Good Manufacturing Practices License for extracting multiple natural cannabinoids. In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany. The company operates in compliance with the laws of the countries in which it operates.

Read more at GlobeNewswire: MediPharm Labs Sets Date to Report Third Quarter 2025